Chargement en cours...
Improved in vivo anti-tumor effects of IgA-Her2 antibodies through half-life extension and serum exposure enhancement by FcRn targeting
Antibody therapy is a validated treatment approach for several malignancies. All currently clinically applied therapeutic antibodies (Abs) are of the IgG isotype. However, not all patients respond to this therapy and relapses can occur. IgA represents an alternative isotype for antibody therapy that...
Enregistré dans:
| Publié dans: | MAbs |
|---|---|
| Auteurs principaux: | , , , , , , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Taylor & Francis
2015
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4966554/ https://ncbi.nlm.nih.gov/pubmed/26466856 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/19420862.2015.1106658 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|